Gwendolyn Barceló-Coblijn

Dr. Gwendolyn Barceló-Coblijn

Lipids in Human Pathology, Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Research Unit - Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120 Palma, Balearic Islands, Spain
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
STS. Terés
S. Terés
Gwendolyn Barceló-CoblijnGwendolyn Barceló-Coblijn
Gwendolyn Barceló-Coblijn
MBM. Benet
M. Benet
RÁR. Álvarez
R. Álvarez
RBR. Bressani
R. Bressani
Pablo V EscribáPablo V Escribá
Pablo V Escribá
Numerous studies have shown that high olive oil intake reduces blood pressure (BP). These positive effects of olive oil have frequently been ascribed to its minor components, such as α-tocopherol, polyphenols, and other phenolic compounds that are not present in other oils. However, in this study we demonstrate that the hypotensive effect of olive oil is caused by its high oleic acid (OA) content (≈70–80%). We propose that olive oil intake increases OA levels in membranes, which regulates membrane lipid structure (H II phase propensity) in such a way as to control G protein-mediated signaling, causing a reduction in BP. This effect is in part caused by its regulatory action on G protein-associated cascades that regulate adenylyl cyclase and phospholipase C. In turn, the OA analogues, elaidic and stearic acids, had no hypotensive activity, indicating that the molecular mechanisms that link membrane lipid structure and BP regulation are very specific. Similarly, soybean oil (with low OA content) did not reduce BP. This study demonstrates that olive oil induces its hypotensive effects through the action of OA.

21 May 2008 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
Pablo V EscribáPablo V Escribá
Pablo V Escribá
jose antonio larrosajose antonio larrosa
jose antonio larrosa
FGFélix M. Goñi
Félix M. Goñi
PKPaavo K. J. Kinnunen
Paavo K. J. Kinnunen
LVLászlo Vigh
Lászlo Vigh
Gwendolyn Barceló-CoblijnGwendolyn Barceló-Coblijn
Gwendolyn Barceló-Coblijn
Membranes constitute a meeting point for lipids and proteins. Not only do they define the entity of cells and cytosolic organelles but they also display a wide variety of important functions previously ascribed to the activity of proteins alone. Indeed, lipids have commonly been considered a mere support for the transient or permanent association of membrane proteins, while acting as a selective cell/organelle barrier. However, mounting evidence demonstrates that lipids themselves regulate the location and activity of many membrane proteins, as well as defining membrane microdomains that serve as spatio-temporal platforms for interacting signalling proteins. Membrane lipids are crucial in the fission and fusion of lipid bilayers and they also act as sensors to control environmental or physiological conditions. Lipids and lipid structures participate directly as messengers or regulators of signal transduction. Moreover, their alteration has been associated with the development of numerous diseases. Proteins can interact with membranes through lipid co-/post-translational modifications, and electrostatic and hydrophobic interactions, van der Waals forces and hydrogen bonding are all involved in the associations among membrane proteins and lipids. The present study reviews these interactions from the molecular and biomedical point of view, and the effects of their modulation on the physiological activity of cells, the aetiology of human diseases and the design of clinical drugs. In fact, the influence of lipids on protein function is reflected in the possibility to use these molecular species as targets for therapies against cancer, obesity, neurodegenerative disorders, cardiovascular pathologies and other diseases, using a new approach called membrane-lipid therapy.

5 March 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KKKlára Kitajka
Klára Kitajka
LPLászló G. Puskás
László G. Puskás
ÁZÁgnes Zvara
Ágnes Zvara
LHLászló Hackler
László Hackler
Gwendolyn Barceló-CoblijnGwendolyn Barceló-Coblijn
Gwendolyn Barceló-Coblijn
TFTibor Farkas
Tibor Farkas
Rats were fed either a high linolenic acid (perilla oil) or high eicosapentaenoic + docosahexaenoic acid (fish oil) diet (8%), and the fatty acid and molecular species composition of ethanolamine phosphoglycerides was determined. Gene expression pattern resulting from the feeding of n-3 fatty acids also was studied. Perilla oil feeding, in contrast to fish oil feeding, was not reflected in total fatty acid composition of ethanolamine phosphoglycerides. Levels of the alkenylacyl subclass of ethanolamine phosphoglycerides increased in response to feeding. Similarly, levels of diacyl phosphatidylethanolamine molecular species containing docosahexaenoic acid (18:0/22:6) were higher in perilla-fed or fish oil-fed rat brains whereas those in ethanolamine plasmalogens remained unchanged. Because plasmalogen levels in the brains of rats fed a n-3 fatty acid-enriched diet increased, it is plausible, however, that docosahexaenoic acid taken up from the food or formed from linolenic acid was deposited in this phospholipid subclass. Using cDNA microarrays, 55 genes were found to be overexpressed and 47 were suppressed relative to controls by both dietary regimens. The altered genes included those controlling synaptic plasticity, cytosceleton and membrane association, signal transduction, ion channel formation, energy metabolism, and regulatory proteins. This effect seems to be independent of the chain length of fatty acids, but the n-3 structure appears to be important. Because n-3 polyunsaturated fatty acids have been shown to play an important role in maintaining normal mental functions and docosahexaenoic acid-containing ethanolamine phosphoglyceride (18:0/22:6) molecular species accumulated in response to n-3 fatty acid feeding, a casual relationship between the two events can be surmised.

1 November 2005 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
CEChristopher E. Ellis
Christopher E. Ellis
EMEric J. Murphy
Eric J. Murphy
DMDrake C. Mitchell
Drake C. Mitchell
MGMikhail Y. Golovko
Mikhail Y. Golovko
FSFernando Scaglia
Fernando Scaglia
RNRobert L. Nussbaum
Robert L. Nussbaum
The presynaptic protein α-synuclein, implicated in Parkinson disease (PD), binds phospholipids and has a role in brain fatty acid (FA) metabolism. In mice lacking α-synuclein (Snca−/−), total brain steady-state mass of the mitochondria-specific phospholipid, cardiolipin, is reduced 22% and its acyl side chains show a 51% increase in saturated FAs and a 25% reduction in essential n-6, but not n-3, polyunsaturated FAs. Additionally, 23% reduction in phosphatidylglycerol content, the immediate biosynthetic precursor of cardiolipin, was observed without alterations in the content of other brain phospholipids. Consistent with these changes, more ordered lipid head group and acyl chain packing with enhanced rotational motion of diphenylhexatriene (DPH) about its long axis were demonstrated in time-resolved DPH fluorescence lifetime experiments. These abnormalities in mitochondrial membrane properties were associated with a 15% reduction in linked complex I/III activity of the electron transport chain, without reductions in mitochondrial number, complex II/III activity, or individual complex I, II, III, or IV activity. Reduced complex I activity is thought to be a critical factor in the development of PD. Thus, altered membrane composition and structure and impaired complex I/III function in Snca−/− brain suggest a relationship between α-synuclein9s role in brain lipid metabolism, mitochondrial function, and PD.

21 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Gwendolyn Barceló-CoblijnGwendolyn Barceló-Coblijn
Gwendolyn Barceló-Coblijn
MMMaria Laura Martin
Maria Laura Martin
RARodrigo F. M. de Almeida
Rodrigo F. M. de Almeida
MNMaria Antònia Noguera-Salvà
Maria Antònia Noguera-Salvà
AMAmaia Marcilla-Etxenike
Amaia Marcilla-Etxenike
Pablo V EscribáPablo V Escribá
Pablo V Escribá
The mechanism of action of 2-hydroxyoleic acid (2OHOA), a potent antitumor compound, has not yet been fully elucidated. Here, we show that human cancer cells have markedly lower levels of sphingomyelin (SM) than nontumor (MRC-5) cells. In this context, 2OHOA treatment strongly augments SM mass (4.6-fold), restoring the levels found in MRC-5 cells, while a loss of phosphatidylethanolamine and phosphatidylcholine is observed (57 and 30%, respectively). The increased SM mass was due to a rapid and highly specific activation of SM synthases (SMS). This effect appeared to be specific against cancer cells as it did not affect nontumor MRC-5 cells. Therefore, low SM levels are associated with the tumorigenic transformation that produces cancer cells. SM accumulation occurred at the plasma membrane and caused an increase in membrane global order and lipid raft packing in model membranes. These modifications would account for the observed alteration by 2OHOA in the localization of proteins involved in cell apoptosis (Fas receptor) or differentiation (Ras). Importantly, SMS inhibition by D609 diminished 2OHOA effect on cell cycle. Therefore, we propose that the regulation of SMS activity in tumor cells is a critical upstream event in 2OHOA antitumor mechanism, which also explains its specificity for cancer cells, its potency, and the lack of undesired side effects. Finally, the specific activation of SMS explains the ability of this compound to trigger cell cycle arrest, cell differentiation, and autophagy or apoptosis in cancer cells.